No Data
No Data
No Data
No Data
No Data
Sanyuan Biotech (301206): Performance is in line with market expectations, 1Q24 erythritol sales picked up
The 2023 and 1Q24 results are in line with market expectations Sanyuan Biotech announced 2023 results: achieved revenue of 500 million yuan, a year-on-year decrease of 25.99%; net profit to mother was 59 million yuan, corresponding to earnings per share of 0.2 billion yuan
中金公司Apr 30 13:21
Sanyuan Biotech (301206.SZ) announced first-quarter results, net profit of 24.2477 million yuan, an increase of 210.54% year-on-year
Sanyuan Biotech (301206.SZ) released its report for the first quarter of 2024. The company's revenue was 192 million yuan, up 65.03% year on year; net profit attributable to shareholders of listed companies was 24.2477 million yuan, up 210.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 238.18,600 yuan, up 226.72% year on year; basic earnings per share were 0.12 yuan/share.
Zhitong FinanceApr 22 22:44
Express News | Sanyuan Biology: Vicious competition at low prices in the erythritol industry has improved markedly
BreakingsApr 19 09:30
Express News | Sanyuan Biotech: Net profit is expected to increase 194.56%-271.4% year-on-year in the first quarter
BreakingsApr 1 16:55
Sanyuan Biotech (301206.SZ) received a warning letter from the Shandong Securities Regulatory Bureau
Sanyuan Biotech (301206.SZ) announced that the company received China Securities Regulatory Administration on February 29, 2024...
Zhitong FinanceMar 1 15:52
Sanyuan Biotech (301206.SZ) actual controller Nie Zaijian and general manager Cheng Baohua completed an increase of 430,200 shares
Sanyuan Biotech (301206.SZ) announcement. As of the disclosure date of this announcement, the company's controlling shareholders, actual controllers, directors...
Zhitong FinanceFeb 20 19:29
No Data
No Data